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ABSTRACT
Objectives: Kosovo’s current health care system does not support organized nationwide cervical cancer screening and 
human papillomavirus (HPV) vaccination programs. To date, no reliable data are available on cervical cancer incidence 
and mortality in Kosovo, or on high-risk HPV (HR-HPV) prevalence and HPV type distribution. Our aim is to determinate 
the pre-vaccination prevalence and distribution of HR-HPVs and to assesses the associations between sociodemographic 
characteristics and increased risk of HPV infection in women from Kosovo. 
Material and methods: Detection of HR-HPV DNA in cytologically evaluated cervical smears was performed using a clini-
cally validated Abbott RealTime High Risk HPV test, Roche Linear Array HPV Genotyping Test, HPV52 type-specific real-time 
PCR and an in-house GP5+/GP6+/68 PCR. 
Results: The crude overall prevalence of any of the HR-HPVs was estimated at 13.1% (26/199; 95% confidence interval 
(CI): 9.1–18.5%), with HPV16 being the most common type (7/26, 26.9%), followed by HPV31 and HPV51, each detected in 
4/26 (15.4%) cervical specimens, HPV18, detected in 3/26 (11.5%) specimens, HPV52 and HPV66, each detected in 2/26 (7.7%) 
specimens, and HPV33, HPV45, HPV56, and HPV58, each detected in a single (3.9%) specimen. Women over 40 (OR = 0.36), 
older than 18 at sexual debut (odds ratio (OR) = 0.28), those that had delivered at least one child (OR = 0.32), and those 
that had a history of pregnancy termination (OR = 0.39) were at lower risk for HPV infection. 
Conclusion: Because more than 70% of cervical precancerous lesions could have been prevented in Kosovo using nation-
wide HPV-based cervical cancer screening and HPV vaccination, it is of outmost importance to implement both programs 
in the national health care system as soon as possible.
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INTRODUCTION
Cervical cancer is the fourth most frequent cancer 
in women; in 2012 and 2015 there were an estimated 
530,000 and 526,000 new cases worldwide, respectively, 
and it was responsible for 266,000 (7.5% of all cancer deaths) 
and 239,000 (6.5% of all cancer deaths) deaths [1, 2]. In 2015, 
one in 68 (1.5%) women developed cervical cancer before 
age 79, with the odds being higher in low-income countries, 
where one in 24 (4.2%) women developed cervical can-
cer, in comparison to high-income countries, where one in 
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115 (0.9%) women developed cervical cancer during their 
lifetime [2]. Between 2005 and 2015, age-standardized inci-
dence rates of cervical cancer decreased globally; however, 
the decline was less prominent in low-income countries [2]. 
Persistent infection with certain types of human papilloma-
viruses (HPV) is a necessary, but non-sufficient, etiological 
factor of cervical cancer [3, 4]. To date, 206 HPV types have 
been identified and officially recognized by the Interna-
tional Human Papillomavirus Reference Center, located at 
the Karolinska Institute in Stockholm, Sweden (http://www.
hpvcenter.se/html/refclones.html). According to their clini-
cal relevance, approximately 40 HPV types from the genus 
Alphapapillomavirus (Alpha-PV) are roughly subdivided into 
high-risk (HR) and low-risk (LR) HPV types. HR-HPVs (Group 
1 carcinogens: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, 
HPV45, HPV51, HPV52, HPV56, HPV58, and HPV59) are etio-
logically associated with more than 98% of cervical cancers, 
70 to 90% of anal and vaginal cancers, 40% of vulvar cancers, 
47% of penile cancers, and 25 to 30% of oropharyngeal can-
cers. In addition, HPV68 is considered probably carcinogenic 
to humans (a Group 2A carcinogen), and HPV26, HPV30, 
HPV34, HPV53, HPV66, HPV67, HPV69, HPV70, HPV73, HPV82, 
HPV85, and HPV97 are classified as possibly carcinogenic to 
humans (Group 2B carcinogens). Low-risk HPV types (mainly 
HPV6 and HPV11) are associated with more than 90% of 
anogenital warts and laryngeal papillomas [3, 4].
Worldwide, the age-adjusted prevalence of HPV infec-
tion in women with normal cervical cytology is estimated at 
10.4%, ranging from 8.1% in Europe to 22.1% in Africa [5]. 
Several global meta-analyses have suggested that the most 
prevalent HPV types in normal cervical cytological specimens 
are HPV16, HPV18, HPV31, HPV52, and HPV58 [5–7]. Moreo-
ver, whereas HPV16 and HPV18 are etiologically associated 
with 71% of cervical cancer cases, this percentage rises to 
more than 90% when including infections with HPV6, HPV11, 
HPV31, HPV33, HPV45, HPV52, and HPV58 [4, 8, 9]. Because 
HPV prevalence and HPV type distribution vary greatly across 
different populations and geographical regions, regional 
HPV prevalence and type distribution studies are important 
before implementing HPV-based cervical cancer screening 
and HPV vaccination in particular countries or regions [5, 8].
Kosovo is a small low-income country with a popula-
tion of 1.7 million in southeastern Europe that has recently 
experienced war and postwar difficulties. Kosovo’s current 
health care system does not support organized nationwide 
cervical cancer screening and HPV vaccination programs. In 
contrast to other countries in the region (e.g. Albania, Bul-
garia, Bosnia and Herzegovina, Croatia, Macedonia, Monte-
negro, Romania, and Serbia), no reliable data are available 
on cervical cancer incidence and mortality in Kosovo, or 
on HR-HPV prevalence and HPV type distribution. Thus, 
the objectives of this study were to determine for the first 
time the pre-vaccination prevalence and distribution of 
HR-HPVs and to assess the associations between particular 
sociodemographic characteristics and increased risk of HPV 
infection in women from Kosovo.
MATERIAL AND METHODS
Specimen and data collection
A total of 199 women, 18 to 63 years old, attending the 
outpatient unit of the Department of Gynecology and Ob-
stetrics, from August 2015 to February 2016, were enrolled 
and had a valid sample for HPV testing. The cohort repre-
sents female population of Kosovo attending the screening 
for cervical cancer. Namely outpatient clinic of the Univer-
sity Clinical Centre of Kosovo (UCCK), based in Prishtina, 
where our study was performed is the only public institu-
tion in Kosovo where the screening for cervical cancer and 
PAP-smear testing are offered to patients in whole country. 
Patients included in the study were randomly selected from 
all patients visiting the outpatient Clinic, were the main 
purpose of the visit of the women was screening for cervical 
cancer or just routine gynaecological examination. All of the 
women provided written informed consent and completed 
a questionnaire on sociodemographic characteristics. Dur-
ing a gynecological examination, one cervical smear was 
obtained for cytological examination, and another cervical 
smear was stored in 1 ml of Digene Specimen Transport 
Medium (STM) (Qiagen, Hilden, Germany) at −20 °C for 
subsequent HPV typing. 
Detection of HPV DNA and HPV typing
Detection of HR-HPV DNA was performed using a clinical-
ly validated RealTime High Risk HPV test (RealTime) (Abbott, 
Wiesbaden, Germany), which enables concurrent individual 
typing for HPV16 and HPV18, as well as pooled detection 
of 12 other carcinogenic HPV types (HPV31, HPV33, HPV35, 
HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV66, 
and HPV68), and also includes an internal process control for 
sample adequacy, DNA extraction, and amplification [10, 11]. 
In addition to several other transport media [10], the assay 
has also been clinically validated for use with cervical speci-
mens collected with Digene STM (Qiagen) [12]. In specimens 
positive for other carcinogenic HPVs, HPV typing was subse-
quently performed using the Linear Array HPV Genotyping 
Test (Roche LA) (Roche Molecular Diagnostics, Branchburg, 
NJ) and, if necessary, also with an HPV52 type-specific re-
al-time PCR assay and an in-house GP5+/GP6+/68 PCR assay, 
as described previously [11, 13, 14].
Statistical analyses
Univariate and multiple logistic regression analyses were 
used to assess the associations between sociodemographic 
characteristics and overall HPV infection. A likelihood ratio 
487
Pranvera Zejnullahu Raçi et al., Pre-vaccination prevalence of high-risk human papillomaviruses (HPV) in women from Kosovo
www. journals.viamedica.pl/ginekologia_polska
test was used to investigate the associations between soci-
odemographic characteristics and HR-HPV types. Associa-
tions with p < 0.05 were treated as statistically significant. 
Analyses were performed with SPSS, version 23.
Ethical statement
This study was performed in compliance with the Dec-
laration of Helsinki and was approved by the Ethics and 
Professional Board of the Ministry of Health of the Republic 
of Kosovo (consent number 05-2826). All women included 
in the study provided written informed consents and only 
their sociodemographic characteristics were available to all 
researchers, preserving patients’ anonymity. 
RESULTS
A total of 199 women, 20 to 63 years old, with a mean age 
of 41.8 years (SD ± 9.3 years) were included in the study (Tab. 
1). The majority of women had graduated from a second-
ary school (107/199, 53.8%), were working as housewives 
or farmers (143/199, 71.9%) and were married (176/199, 
88.4%), were a part of a small family (only parents and their 
children: 141/199, 70.9%) with a sufficient income (104/199, 
52.3%), were at least 18 years old at the time of first sexual 
intercourse (168/199, 84.4%), had given birth to at least 
one child (178/199, 89.4%), had had at least one pregnancy 
terminated (100/199, 50.3%), had a regular menstrual cycle 
(126/199, 63.3%), were not using contraception (166/199, 
83.4%), and were non-smokers (149/199, 74.9%) (Tab. 1). 
The vast majority of women (165/199, 82.9%) had a normal 
cytological result (negative for intra-epithelial lesion or ma-
lignancy, NILM). Atypical squamous cells of undetermined 
significance (ASCUS) were detected in cervical specimens 
of 30/199 (15.1%) women and atypical squamous cells, 
cannot exclude high-grade squamous intraepithelial lesion 
(ASC-H), and cervical cancer were detected in two women, 
respectively (Tab. 1).
Detection and typing of HPV infection
The crude overall prevalence of HR-HPV infection with 
any of the targeted 14 HPV types was estimated at 13.1% 
(26/199, 95% confidence interval (95% CI): 9.1–18.5%) (Tab. 
2). As shown in Table 3, infections with HPV16 were overall 
the most common, followed by HPV31 and HPV51, and 
HPV18. Similarly, HPV16 was also the most frequently detect-
ed HPV type in patients with NILM, followed by HPV31 and 
HPV51 (Tab. 3). Patients with ASCUS were most frequently 
infected with HPV18 (Tab. 3).
Both cervical cancer cases determined by the cytological 
examination were additionally confirmed using histopa-
thology. Even though no multiple HR-HPV infections were 
determined in our study population, using Roche LA and 
an in-house GP5+/GP6+/68 PCR assay, single HPV16 and 
HPV66-positive cervical specimens were additionally posi-
tive for HPV84 and HPV67, respectively, two HPV51-positive 
cervical specimens were additionally positive for HPV53 and 
HPV62, respectively, and the HPV58-positive cervical speci-
men was additionally positive for HPV6 and HPV73.
Association between sociodemographic 
characteristics and HPV infection
As shown in Table 4, using univariate logistic re-
gression analysis to investigate potential differences in 
the sociodemographic characteristics of HPV-negative 
vs. HPV-positive patients, statistically significant asso-
ciations with HPV infection were found only for women’s 
age (p = 0.015), age at the time of first sexual intercourse 
(p = 0.006), delivery (p = 0.026), and history of pregnancy 
termination (p = 0.033). Despite the fact that the preva-
lence of HPV infection was the highest in women 30 to 
39 years old (21.2% (11/52); mean: 20.8%; standard de-
viation SD: ± 6.4), followed by women 20 to 29 years old 
(19.1% (4/21); mean: 19.0%; SD: ± 10.5), 40 to 49 years old 
(9.6% (8/83); mean: 9.6%; SD: ± 4.2), and over 50 (7.0% 
(3/43); mean: 7.0%; SD: ± 5.8) (Fig. 1), the differences were 
not statistically significant (p = 0.127). However, women 
over 40 had lower odds for HPV infection (odds ratio 
(OR) = 0.36; 95% CI: 0.15–0.84) (Tab. 4). Moreover, lower 
odds for HPV infection were also observed among women 
that were at least 18 years old at sexual debut (OR = 0.28; 
95% CI: 0.11–0.69), had given birth to at least one child 
(OR = 0.32; 95% CI: 0.11–0.91), or had a history of preg-
nancy termination (OR = 0.39; 95% CI: 0.16–0.95) (Tab. 4). 
Due to the small number of units in the category of the de-
pendent variable (HPV infection), only three independent 
variables (age at inclusion in the study: up to 40 years old 
and over 40, age at first sexual intercourse: below 18 and 
at least 18 years old or older, and history of delivering at 
least one child), were included in the multiple logistic 
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Figure 1. Age-specific HPV prevalence with standard deviation 
among 199 women from Kosovo included in the study
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Table 1. Socio-demographic characteristics of women included in the study and the results of cytology
N = 199 (%)
(Mean) age (SD) 41.8 (9.3)
< 40 years old 79 (39.7)
> 40 years old 120 (60.3)
Education
Finished elementary school or less 51 (25.6)
Finished secondary school 107 (53.8)
More than secondary school 41 (20.6)
Employment status
Employed 51 (25.6)
Housewife or farmer 143 (71.9)
Student 5 (2.5)
Marital status
Married 176 (88.4)
Divorced/widow 13 (6.5)
Single 10 (5.0)
Family size
Single 4 (2.0)
Small family (parents&children) 141 (70.9)
Large family (parents, children and other family members) 54 (27.1)
Family income*
Insufficient 54 (27.1)
Sufficient 104 (52.3)
Good 41 (20.6)
Age at first sexual intercourse
< 18 years old 31 (15.6)
≥ 18 years old 168 (84.4)
Delivery
Yes 178 (89.4)
No 21 (10.6)
Pregnancy termination
Yes 100 (50.3)
No 99 (49.7)
Menstrual cycle
Regular 126 (63.3)
Irregular 40 (20.1)
Postmenopausal 33 (16.6)
Contraception use
Yes 33 (16.5)
No 166 (83.4)
Smoking
Yes 50 (25.1)
No 149 (74.9)
Cytology
Negative for intra-epithelial lesion or malignancy (NILM) 165 (82.9)
Atypical squamous cells of undetermined significance (ASCUS) 30 (15.1)
Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H) 2 (1.0)
Cervical cancer 2 (1.0)
Categorical and continuous variables are shown as frequencies (percentages) and as mean (standard deviation), respectively. * The family’s financial situation was 
evaluated by patients themselves.
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Table 2. Overall prevalence of HR-HPVs among 199 women from Kosovo according to the cytology results 
HPV types All women (N = 199) Cytology results
N Prevalence (%)(95% CI) NILM (N = 165) ASCUS (N = 30) ASC-H (N = 2) Cervical cancer (N = 2)
N Prevalence (%) (95% CI) N
Prevalence (%)
(95% CI) N
Prevalence (%)
(95% CI) N
Prevalence (%)
(95% CI)
Any HR-HPV 26 13.1 (9.1–18.5) 16 9.7 (6.1–15.2) 7 23.3 (11.8–40.9) 1 50.0 (9.5–90.6) 2 100 (34.2–100)
HPV16/HPV18 10 5.0 (2.8–9.0) 5 3.0 (1.3–6.9) 2 6.7 (1.9–21.3) 1 50.0 (9.5–90.6) 2 100 (34.2–100)
HPV16 7 3.5 (1.7–7.1) 5 3.0 (1.3–6.9) 0 0 (–) 1 50.0 (9.5–90.6) 1 50.0 (9.5–90.5)
HPV18 3 1.5 (0.5–4.3) 0 0 (–) 2 6.7 (1.9–21.3) 0 0 (–) 1 50.0 (9.5–90.5)
HPV31 4 2.0 (0.8–5.1) 3 1.8 (0.6–5.2) 1 3.3 (0.6–16.7) 0 0 (–) 0 0 (–)
HPV33 1 0.5 (0.1–2.8) 1 0.6 (0.1–3.4) 0 0 (–) 0 0 (–) 0 0 (–)
HPV45 1 0.5 (0.1–2.8) 1 0.6 (0.1–3.4) 0 0 (–) 0 0 (–) 0 0 (–)
HPV51 4 2.0 (0.8–5.1) 3 1.8 (0.6–5.2) 1 3.3 (0.6–16.7) 0 0 (–) 0 0 (–)
HPV52 2 1.0 (0.3–3.6) 1 0.6 (0.1–3.4) 1 3.3 (0.6–16.7) 0 0 (–) 0 0 (–)
HPV56 1 0.5 (0.1–2.8) 1 0.6 (0.1–3.4) 0 0 (–) 0 0 (–) 0 0 (–)
HPV58 1 0.5 (0.1–2.8) 0 0 (–) 1 3.3 (0.6–16.7) 0 0 (–) 0 0 (–)
HPV66 2 1.0 (0.3–3.6) 1 0.6 (0.1–3.4) 1 3.3 (0.6–16.7) 0 0 (–) 0 0 (–)
Abbreviations — NILM (negative for intra-epithelial lesion or malignancy); ASCUS — atypical squamous cells of undetermined significance; ASC-H — atypical squamous 
cells, cannot exclude high-grade squamous intraepithelial lesion; 95% CI — 95% confidence interval
Table 3. Distribution of HR-HPV types among 26 women infected with any of the 14 HR-HPVs according to the cytology results
HPV types N % Cytology results
NILM ASCUS ASC-H Cervical cancer 
N % N % N % N %
Any HR-HPV 26 100 16 100 7 100 1 100 2 100
HPV16/HPV18 10 38.5 5 31.3 2 28.6 1 100 2 100
HPV16 7 26.9 5 31.3 0 0 1 100 1 50.0
HPV18 3 11.5 0 0 2 28.6 0 0 1 50.0
HPV31 4 15.4 3 18.8 1 14.3 0 0 0 0
HPV33 1 3.9 1 6.3 0 0 0 0 0 0
HPV45 1 3.9 1 6.3 0 0 0 0 0 0
HPV51 4 15.9 3 18.8 1 14.3 0 0 0 0
HPV52 2 7.7 1 6.3 1 14.3 0 0 0 0
HPV56 1 3.9 1 6.3 0 0 0 0 0 0
HPV58 1 3.9 0 0 1 14.3 0 0 0 0
HPV66 2 7.7 1 6.3 1 14.3 0 0 0 0
Abbreviations — NILM (negative for intra-epithelial lesion or malignancy); ASCUS — atypical squamous cells of undetermined significance); ASC-H — atypical 
squamous cells, cannot exclude high-grade squamous intraepithelial lesion
regression analysis. When controlling for other varia bles 
in the model, all three independent variables were sta-
tistically significantly associated with HPV infection, with 
OR = 0.37 (95% CI: 0.15–0.94) and p = 0.036 for overall older 
age (over 40 years old), OR = 0.18 (95% CI: 0.06–0.50) and 
p < 0.001 for older age at sexual debut (at least 18 years 
old), and OR = 0.28 (95% CI: 0.09–0.92) and p = 0.035 for 
history of delivering at least one child. The results of the 
multiple logistic regression analysis therefore suggest that 
women younger than 40, who were younger than 18 at the 
time of first sexual intercourse and that have not yet given 
birth, are at greater risk for HPV infection [Fig. 1].
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Table 4. Association between socio-demographic characteristics and HPV infection (results of an univariate logistic regression analysis)
HPV-negative (n = 173) HPV-positive (n = 26) OR (95% CI) P-value
(Mean) age (SD) 42.4 (9.2) 38.4 (9.9) 0.96 (0.91; 1) 0.044
< 40 years old 63 (36.4) 16 (61.5) 1
> 40 years old 110 (63.6) 10 (38.5) 0.36 (0.15; 0.84) 0.015
Education
Finished elementary school or less 45 (26) 6 (23.1) 1
Finished secondary school 92 (53.2) 15 (57.7) 1.22 (0.44; 3.36) 0.697
More than secondary school 36 (20.8) 5 (19.2) 1.04 (0.29; 3.69) 0.950
Employment status
Employed 44 (25.4) 7 (26.9) 1
Housewife or farmer 125 (72.3) 18 (69.2) 0.91 (0.35; 2.31) 0.835
Student 4 (2.3) 1 (3.8) 1.57 (0.15; 6.18) 0.702
Marital status
Divorced/widowed 10 (5.8) 3 (11.5) 1
Married 155 (89.6) 21 (80.8) 0.45 (0.11; 1.77) 0.244
Single 8 (4.6) 2 (7.7) 0.83 (0.11; 6.26) 0.859
Family size
Single 3 (1.7) 1 (3.8) 1
Small family (parents&children) 124 (71.7) 17 (65.4) 0.41 (0.04; 4.18) 0.453
Large family (parents, children and other 
family members) 46 (26.6) 8 (30.8) 0.52 (0.05; 5.66) 0.593
Family income*
Insufficient 47 (27.2) 7 (26.9) 1
Sufficient 88 (50.9) 16 (61.5) 1.22 (0.47; 3.18) 0.683
Good 38 (22) 3 (11.5) 0.53 (0.13; 2.19) 0.380
(Mean) age (SD) at first sexual intercourse 21.9 (4.2) 20.8 (5.4) 0.94 (0.84; 1.04) 0.230
< 18 years old 22 (12.7) 9 (34.6) 1
> 18 years old 151 (87.3) 17 (65.4) 0.28 (0.11; 0.69) 0.006
Delivery
No 15 (8.7) 6 (23.1) 1
Yes 158 (91.3) 20 (76.9) 0.32 (0.11; 0.91) 0.026
Pregnancy termination
No 81 (46.8) 18 (69.2) 1
Yes 92 (53.2) 8 (30.8) 0.39 (0.16; 0.95) 0.033
Menstrual cycle
Irregular 33 (19.1) 7 (26.9) 1
Regular 108 (62.4) 18 (69.2) 0.79 (0.30; 2.04) 0.620
Postmenopausal 32 (18.5) 1 (3.8) 0.15 (0.02; 1.27) 0.081
Contraception
No 145 (83.8) 21 (80.8) 1
Yes 28 (16.2) 5 (19.2) 1.23 (0.43; 3.54) 0.697
Smoking
No 131 (75.7) 18 (69.2) 1
Yes 42 (24.3) 8 (30.8) 1.39 (0.56; 3.42) 0.477
Categorical and continuous variables are shown as frequencies (percentages) and as mean (standard deviation), respectively. * The family’s financial situation was 
evaluated by patients themselves. Abbreviations — OR (odds ratio); 95% CI — 95% confidence interval
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Association between sociodemographic 
characteristics and HR-HPV types
As shown in Table 5, the results of the likelihood ratio 
test suggested that women infected with HPV16 were older 
in comparison to women infected with other HR-HPV types 
(p = 0.037). In addition, all women infected with HPV16 have 
given birth to at least one child, whereas only 68.4% of 
women infected with other HR-HPVs had biological chil-
dren (p = 0.036). Other characteristics were not statistically 
significantly associated with specific HR-HPV types.
DISCUSSION
Infections with over 40 HPV types from the clinically 
most important Alpha-PV genus are considered to be the 
most frequently sexually transmitted infections in both 
genders. In addition, worldwide, up to 4.5% of incident 
cancer cases, including cervical, anogenital, and head and 
neck cancers, are etiologically associated with HPV infection. 
Moreover, cervical cancer accounts for 83% of all HPV-relat-
ed cancers, with the majority occurring in women originat-
ing from less-developed countries [4].
In the female population from Kosovo, the crude overall 
prevalence of infection with any of the 14 HR-HPVs was 
estimated at 13.1%. Interestingly, in our study population 
the overall HR-HPV prevalence in NILM was lower than in 
studies on a total of 10.744 eligible women from other coun-
tries in central and eastern Europe (9.7%; 95% CI: 6.1–15.2% 
vs. 18.0%; 95% CI: 17.0–19.0%, respectively) [15–23], with 
reported high incidence rates of cervical cancer and re-
lated mortality rates [1]. Our results were concordant with 
those obtained in the largest study in the region to date, 
performed on 4.199 Slovenian women (HR-HPV prevalence 
of 10.7%; cervical cancer incidence rate per 100,000: 13.4; 
mortality rate due to cervical cancer per 100,000: 6.1) [1, 14], 
as well as with global data (HR-HPV prevalence of 10.4%; 
cervical cancer incidence rate per 100,000: 15.1; mortality 
rate due to cervical cancer per 100,000: 7.6) [1, 5].
Three prophylactic HPV vaccines are commer-
cially available: a bivalent HPV16/18 vaccine (Cervarix; 
GlaxoSmithKline Biologicals, Belgium), a quadrivalent 
HPV6/11/16/18 vaccine (Gardasil/Silgard; Merck & Co., 
USA / Sanofi Pasteur MSD, France), and a nonavalent 
HPV6/11/16/18/31/33/45/52/58 vaccine (Gardasil9, Merck 
& Co.). After the first 10 years of routine use of HPV vac-
cines, comprehensive clinical trials and real-life data have 
confirmed the vaccines’ safety and effectiveness.
Even though the introduction of HPV vaccination has the 
potential to substantially reduce the incidence of cervical 
cancer cases, the full effect on women of all ages will be de-
tectable no sooner than after 30 years. Thus well-organized 
cervical cancer screening programs will still play a crucial 
role in the prevention of cervical cancer and bridging the 
gap until the full effect of HPV vaccines can be observed 
[24]. Vaccarella et al. estimated recently that, with the im-
plementation of well-organized cervical cancer screening 
by 2017 in six Baltic, central European, and eastern Euro-
pean countries (Estonia, Lithuania, Latvia, Belarus, Bulgaria, 
and Russia), in which cervical cancer screening is absent 
or, at best, opportunistic with low coverage and quality, 
180,000 new cervical cancer cases could be prevented from 
2017 to 2040 [24]. In comparison to cytology-based screen-
ing, HPV-based screening is more effective and efficient 
for the prevention of invasive cervical cancer. Therefore, 
HPV testing is an invaluable part of guidelines for cervical 
cancer screening, triage, and follow-up after treatment [24]. 
Even though more than 190 distinct HPV tests and at least 
127 test variants were commercially available in 2015, only 
a fraction of HPV tests fulfill the criteria for use in primary 
cervical cancer screening, with RealTime, used in this study, 
being one of them [25]. The World Health Organization sug-
gests that, in countries without established cytology-based 
cervical cancer screening, HPV-based screening programs, in 
combination with the implementation of HPV vaccination, 
could further accelerate screening benefits and reduce the 
burden of cervical cancer [24].
Despite the fact that a comprehensive strategy, includ-
ing HPV vaccination and HPV-based cervical cancer screen-
ing, has been demonstrated to be cost-effective in nearly all 
countries [26], progress toward prevention is often hindered 
due to relatively low access to vaccines [27] and limited use 
of cervical cancer screening [28], especially in low-income 
countries.
We hope that the results of this study will also persuade 
the authorities to implement nationwide cervical cancer 
screening and HPV vaccination programs in Kosovo.
Even though multiple HPV infections are not uncom-
mon in cervical specimens, each HPV type is associated with 
a biologically separate and independent cervical lesion, as 
observed using laser capture micro-dissection (LCM) with 
HPV PCR typing (LCM-PCR) [29]. In our study, multiple HPV 
types were detected in five cervical smears (HPV16+HPV84, 
HPV66+HPV67, HPV51+53, HPV51+62, and HPV6+58+73). 
Although the cycle threshold values obtained using the 
RealTime were higher for HR-HPV types in comparison to 
other HPVs, suggesting the predominance of HR-HPVs, it 
is impossible to speculate on the etiological associations 
because the LCM-PCR technique cannot be used on smear 
samples.
Because persistent infection with HR-HPVs is a neces-
sary, but non-sufficient, etiological factor of cervical cancer, 
several contributory factors have been described previously 
[3, 4, 30]. In this study, the results of the univariate and 
multiple logistic regression analyses suggested that women 
over 40 (univariate logistic regression: p = 0.015, OR = 0.36; 
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Table 5. Association between socio-demographic characteristics and HR-HPV types (results of likelihood ratio test)
Other HPV type (n = 19) HPV16 (n = 7) P-value
Age
< 40 years old 14 (73.7) 2 (28.6) 0.037
> 40 years old 5 (26.3) 5 (71.4)
Education
Finished elementary school or less 6 (31.6) 0 (0) 0.107
Finished secondary school 10 (52.6) 5 (71.4)
More than secondary school 3 (15.8) 2 (28.6)
Employment status
Eemployed 5 (26.3) 2 (28.6) 0.725
Housewife or farmer 13 (68.4) 5 (71.4)
Student 1 (5.3) 0 (0)
Marital status
Married 15 (78.9) 6 (85.7) 0.303
Divorced/widowed 3 (15.8) 0 (0)
Single 1 (5.3) 1 (14.3)
Family size
Single 1 (5.3) 0 (0) 0.706
Small (parents&children) 12 (63.2) 5 (71.4)
Large (parents, children and other family 
members) 6 (31.6) 2 (28.6)
Family income*
Insufficient 6 (31.6) 1 (14.3) 0.652
Sufficient 11 (57.9) 5 (71.4)
Good 2 (10.5) 1 (14.3)
Age at first sexual intercourse
< 18 7 (36.8) 2 (28.6) 0.691
> 18 12 (63.2) 5 (71.4)
Delivery
Yes 13 (68.4) 7 (100) 0.036
No 6 (31.6) 0 (0)
Pregnancy termination
Yes 6 (31.6) 2 (28.6) 0.882
No 13 (68.4) 5 (71.4)
Menstrual cycle
Regular 13 (68.4) 5 (71.4) 0.725
Irregular 5 (26.3) 2 (28.6)
Postmenopausal 1 (5.3) 0 (0)
Contraception
Yes 4 (21.1) 1 (14.3) 0.691
No 15 (78.9) 6 (85.7)
Smoking
Yes 6 (31.6) 2 (28.6) 0.882
No 13 (68.4) 5 (71.4)
* The family’s financial situation was evaluated by patients themselves.
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multiple logistic regression: p = 0.036, OR = 0.37), who were 
older than 18 at sexual debut (univariate logistic regression: 
p = 0.006, OR = 0.28; multiple logistic regression: p < 0.001, 
OR = 0.18), and those with a history of delivering at least 
one child (univariate logistic regression: p = 0.026, OR = 0.32; 
multiple logistic regression: p = 0.035, OR = 0.28) were at 
lower risk for HPV infection. The results of the univariate lo-
gistic regression analysis additionally suggested that wom-
en with a history of pregnancy termination also have lower 
odds (p = 0.033, OR = 0.39) for HPV infection. Our results 
are concordant with global data (reviewed in 30), reporting 
that the incidence/prevalence of HPV infection peaks at 
a younger age (below 25–35 years), soon after the start of 
sexual activity, and declines with age due to the spontane-
ous clearance of HPV infections. Similarly as in our study, 
associations between cervical cancer, cervical intraepithelial 
lesions, and increasing number of pregnancies and parity 
were also found in previous case-control studies (reviewed 
in 30). Interestingly, according to the likelihood ratio test, in 
comparison to women infected with other HR-HPV types, 
women infected with HPV16 were older (p = 0.037) and have 
given birth to at least one child (p = 0.036).
CONCLUSIONS
In conclusion, this study is the first study reporting the 
HR-HPV prevalence and distribution of HPV types in Kosovo. 
Because more than 70% of cervical precancerous lesions 
identified in the study could have been prevented using 
nationwide HPV-based cervical cancer screening and HPV 
vaccination programs, it is of outmost importance to imple-
ment both programs in the national health care system in 
Kosovo as soon as possible.
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